Entrada Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRDA research report →
Companywww.entradatx.com
Entrada Therapeutics, Inc. , a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
- CEO
- Dipal Doshi
- IPO
- 2021
- Employees
- 183
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $234.09M
- P/E
- -1.52
- P/S
- 40.74
- P/B
- 0.93
- EV/EBITDA
- -1.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -598.01%
- Op Margin
- -3109.29%
- Net Margin
- -2895.05%
- ROE
- -51.22%
- ROIC
- -55.65%
Growth & Income
- Revenue
- $25.42M · -87.94%
- Net Income
- $-143,750,000 · -319.04%
- EPS
- $-3.47 · -297.16%
- Op Income
- $-155,998,000
- FCF YoY
- -189.73%
Performance & Tape
- 52W High
- $16.45
- 52W Low
- $4.93
- 50D MA
- $12.03
- 200D MA
- $9.33
- Beta
- -0.09
- Avg Volume
- 348.93K
Get TickerSpark's AI analysis on TRDA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 4, 26 | Sethuraman Natarajan | sell | 25,907 |
| May 4, 26 | Dowden Nathan J | other | 15,000 |
| May 4, 26 | Dowden Nathan J | sell | 15,000 |
| May 4, 26 | Dowden Nathan J | other | 15,000 |
| Apr 1, 26 | WENTWORTH KORY JAMES | sell | 2,500 |
| Mar 9, 26 | Dowden Nathan J | sell | 3,116 |
| Mar 10, 26 | Dowden Nathan J | sell | 11,894 |
| Mar 9, 26 | WENTWORTH KORY JAMES | sell | 5,089 |
| Mar 10, 26 | WENTWORTH KORY JAMES | sell | 11,388 |
| Mar 4, 26 | WENTWORTH KORY JAMES | sell | 7,988 |
Our TRDA Coverage
We haven't published any research on TRDA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRDA Report →